Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced MelanomaJournal of clinical oncology, 2023-01, Vol.41 (3), p.528-540 [Peer Reviewed Journal]2022 by American Society of Clinical Oncology 2022 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.22.00343 ;PMID: 35998300Full text available |
|
2 |
Material Type: Article
|
SnapShot: Cancer Immunotherapy with Oncolytic VirusesCell, 2019-02, Vol.176 (5), p.1240-1240.e1 [Peer Reviewed Journal]2019 ;Copyright © 2019. Published by Elsevier Inc. ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2019.01.051 ;PMID: 30794777Full text available |
|
3 |
Material Type: Article
|
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant GliomaJournal of clinical oncology, 2018-05, Vol.36 (14), p.1419-1427 [Peer Reviewed Journal]2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2017.75.8219 ;PMID: 29432077Full text available |
|
4 |
Material Type: Article
|
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid TumorsCancer cell, 2020-10, Vol.38 (4), p.454-472 [Peer Reviewed Journal]2020 ;Published by Elsevier Inc. ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccell.2020.07.013 ;PMID: 32822573Full text available |
|
5 |
Material Type: Article
|
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV MelanomaJournal of clinical oncology, 2016-08, Vol.34 (22), p.2619-2626 [Peer Reviewed Journal]2016 by American Society of Clinical Oncology. ;2016 by American Society of Clinical Oncology 2016 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2016.67.1529 ;PMID: 27298410Full text available |
|
6 |
Material Type: Article
|
Optimizing oncolytic virotherapy in cancer treatmentNature reviews. Drug discovery, 2019-09, Vol.18 (9), p.689-706 [Peer Reviewed Journal]Copyright Nature Publishing Group Sep 2019 ;Springer Nature Limited 2019. ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/s41573-019-0029-0 ;PMID: 31292532Full text available |
|
7 |
Material Type: Article
|
Intratumoural administration and tumour tissue targeting of cancer immunotherapiesNature reviews. Clinical oncology, 2021-09, Vol.18 (9), p.558-576 [Peer Reviewed Journal]2021. Springer Nature Limited. ;COPYRIGHT 2021 Nature Publishing Group ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1759-4774 ;EISSN: 1759-4782 ;DOI: 10.1038/s41571-021-00507-y ;PMID: 34006998Full text available |
|
8 |
Material Type: Article
|
Oncolytic virus therapy: A new era of cancer treatment at dawnCancer science, 2016-10, Vol.107 (10), p.1373-1379 [Peer Reviewed Journal]2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. ;2016. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1347-9032 ;EISSN: 1349-7006 ;DOI: 10.1111/cas.13027 ;PMID: 27486853Full text available |
|
9 |
Material Type: Article
|
Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus ImmunotherapyClinical cancer research, 2016-03, Vol.22 (5), p.1048-1054 [Peer Reviewed Journal]2015 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-15-2667 ;PMID: 26719429Full text available |
|
10 |
Material Type: Article
|
An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets GlioblastomaCancer research (Chicago, Ill.), 2021-07, Vol.81 (13), p.3635-3648 [Peer Reviewed Journal]2021 American Association for Cancer Research. ;ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/0008-5472.CAN-21-0035 ;PMID: 34006525Full text available |
|
11 |
Material Type: Article
|
Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumorsCancer research (Chicago, Ill.), 2014-09, Vol.74 (18), p.5195-5205 [Peer Reviewed Journal]2014 American Association for Cancer Research. ;ISSN: 0008-5472 ;EISSN: 1538-7445 ;DOI: 10.1158/0008-5472.CAN-14-0697 ;PMID: 25060519Full text available |
|
12 |
Material Type: Article
|
Immunotherapy for hepatocellular carcinoma: Current and futureWorld journal of gastroenterology : WJG, 2019-06, Vol.25 (24), p.2977-2989The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. 2019 ;ISSN: 1007-9327 ;EISSN: 2219-2840 ;DOI: 10.3748/wjg.v25.i24.2977 ;PMID: 31293335Full text available |
|
13 |
Material Type: Article
|
Oncolysis without viruses - inducing systemic anticancer immune responses with local therapiesNature reviews. Clinical oncology, 2020-01, Vol.17 (1), p.49-64 [Peer Reviewed Journal]COPYRIGHT 2020 Nature Publishing Group ;Copyright Nature Publishing Group Jan 2020 ;ISSN: 1759-4774 ;ISSN: 1759-4782 ;EISSN: 1759-4782 ;DOI: 10.1038/s41571-019-0272-7 ;PMID: 31595049Full text available |
|
14 |
Material Type: Article
|
Intratumoral Immunotherapy: From Trial Design to Clinical PracticeClinical cancer research, 2021-02, Vol.27 (3), p.665-679 [Peer Reviewed Journal]2020 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-20-0473 ;PMID: 32943460Full text available |
|
15 |
Material Type: Article
|
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine GliomaThe New England journal of medicine, 2022-06, Vol.386 (26), p.2471-2481 [Peer Reviewed Journal]Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;COPYRIGHT 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2202028 ;PMID: 35767439Full text available |
|
16 |
Material Type: Article
|
Cancer immunotherapy comes of age and looks for maturityNature communications, 2020-07, Vol.11 (1), p.3325-3325, Article 3325 [Peer Reviewed Journal]The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-020-17140-5 ;PMID: 32620755Full text available |
|
17 |
Material Type: Article
|
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against CancerFrontiers in immunology, 2018-04, Vol.9, p.866-866 [Peer Reviewed Journal]Copyright © 2018 Marelli, Howells, Lemoine and Wang. 2018 Marelli, Howells, Lemoine and Wang ;ISSN: 1664-3224 ;EISSN: 1664-3224 ;DOI: 10.3389/fimmu.2018.00866 ;PMID: 29755464Full text available |
|
18 |
Material Type: Article
|
Oncolytic Virus Combination Therapy: Killing One Bird with Two StonesMolecular therapy, 2018-06, Vol.26 (6), p.1414-1422 [Peer Reviewed Journal]2018 The American Society of Gene and Cell Therapy ;Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved. ;2018. The American Society of Gene and Cell Therapy ;2018 The American Society of Gene and Cell Therapy. 2018 The American Society of Gene and Cell Therapy ;ISSN: 1525-0016 ;EISSN: 1525-0024 ;DOI: 10.1016/j.ymthe.2018.04.001 ;PMID: 29703699Full text available |
|
19 |
Material Type: Article
|
Talimogene laherparepvec: First in class oncolytic virotherapyHuman vaccines & immunotherapeutics, 2018-04, Vol.14 (4), p.839-846 [Peer Reviewed Journal]2018 The Author(s). Published with license by Taylor & Francis 2018 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2017.1412896 ;PMID: 29420123Full text available |
|
20 |
Material Type: Article
|
NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor ImmunotherapyClinical cancer research, 2022-04, Vol.28 (7), p.1460-1473 [Peer Reviewed Journal]2022 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.ccr-21-2347 ;PMID: 35022322Full text available |